Anti-FUCO2/ FUCA2/ dJ20N2.5 functional antibody
Anti-FUCO2/ FUCA2/ dJ20N2.5 functional antibody for cell culture, ELISA & in-vivo assay
Go to FUCA2/FUCA2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-SE0618-Ab-1/ GM-Tg-hg-SE0618-Ab-2 | Anti-Human FUCA2 monoclonal antibody | Human |
| GM-Tg-rg-SE0618-Ab-1/ GM-Tg-rg-SE0618-Ab-2 | Anti-Rat FUCA2 monoclonal antibody | Rat |
| GM-Tg-mg-SE0618-Ab-1/ GM-Tg-mg-SE0618-Ab-2 | Anti-Mouse FUCA2 monoclonal antibody | Mouse |
| GM-Tg-cynog-SE0618-Ab-1/ GM-Tg-cynog-SE0618-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FUCA2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-SE0618-Ab-1/ GM-Tg-felg-SE0618-Ab-2 | Anti-Feline FUCA2 monoclonal antibody | Feline |
| GM-Tg-cang-SE0618-Ab-1/ GM-Tg-cang-SE0618-Ab-2 | Anti-Canine FUCA2 monoclonal antibody | Canine |
| GM-Tg-bovg-SE0618-Ab-1/ GM-Tg-bovg-SE0618-Ab-2 | Anti-Bovine FUCA2 monoclonal antibody | Bovine |
| GM-Tg-equg-SE0618-Ab-1/ GM-Tg-equg-SE0618-Ab-2 | Anti-Equine FUCA2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-SE0618-Ab-1/ GM-Tg-hg-SE0618-Ab-2; GM-Tg-rg-SE0618-Ab-1/ GM-Tg-rg-SE0618-Ab-2; GM-Tg-mg-SE0618-Ab-1/ GM-Tg-mg-SE0618-Ab-2; GM-Tg-cynog-SE0618-Ab-1/ GM-Tg-cynog-SE0618-Ab-2; GM-Tg-felg-SE0618-Ab-1/ GM-Tg-felg-SE0618-Ab-2; GM-Tg-cang-SE0618-Ab-1/ GM-Tg-cang-SE0618-Ab-2; GM-Tg-bovg-SE0618-Ab-1/ GM-Tg-bovg-SE0618-Ab-2; GM-Tg-equg-SE0618-Ab-1/ GM-Tg-equg-SE0618-Ab-2 |
| Products Name | Anti-FUCA2 monoclonal antibody |
| Format | mab |
| Target Name | FUCA2 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-FUCA2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-SE0618-Ag-1 | Recombinant multi-species FUCO2/ FUCA2/ dJ20N2.5 protein |
Target information
| Target ID | GM-SE0618 |
| Target Name | FUCA2 |
| Gene ID | 2519,66848,292485,700611,484016,101095340,515729,100067102 |
| Gene Symbol and Synonyms | 0610025O11Rik,5530401P20Rik,dJ20N2.5,FUCA2 |
| Uniprot Accession | Q9BTY2,Q6AYS4 |
| Uniprot Entry Name | FUCO2_HUMAN,FUCO2_RAT |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000001036 |
| Target Classification | N/A |
The target: FUCA2, gene name: FUCA2, also named as dJ20N2.5. This gene encodes a plasma alpha-L-fucosidase, which represents 10-20% of the total cellular fucosidase activity. The protein is a member of the glycosyl hydrolase 29 family, and catalyzes the hydrolysis of the alpha-1,6-linked fucose joined to the reducing-end N-acetylglucosamine of the carbohydrate moieties of glycoproteins. This enzyme is essential for Helicobacter pylori adhesion to human gastric cancer cells. [provided by RefSeq, Aug 2010].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

